Hims & Hers Health (NYSE:HIMS) CFO Oluyemi Okupe Sells 145,000 Shares

Key Points

• Oluyemi Okupe, CFO of Hims & Hers Health, sold 145,000 shares of stock at an average price of $55.35, totaling approximately $8.03 million, resulting in a 52.92% decrease in his ownership.
• The company's stock has seen a 1.1% decrease and is currently trading at $50.32, with a market capitalization of $11.37 billion.
• Recent earnings showed $0.17 EPS, missing the consensus estimate of $0.18, with revenues up 72.6% year-over-year but still below expectations.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 145,000 shares of the business's stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $55.35, for a total transaction of $8,025,750.00. Following the transaction, the chief financial officer directly owned 128,984 shares of the company's stock, valued at $7,139,264.40. The trade was a 52.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Oluyemi Okupe also recently made the following trade(s):

• On Tuesday, August 26th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The shares were sold at an average price of $43.69, for a total transaction of $505,973.89.
• On Monday, July 14th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The stock was sold at an average price of $47.70, for a total transaction of $552,413.70.
• On Monday, July 7th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The stock was sold at an average price of $46.67, for a total transaction of $540,485.27.
• On Monday, June 23rd, Oluyemi Okupe sold 23,107 shares of Hims & Hers Health stock. The shares were sold at an average price of $47.25, for a total transaction of $1,091,805.75.

Hims & Hers Health Trading Up 2.7%

Shares of HIMS stock traded up $1.54 on Friday, hitting $57.74. 36,152,647 shares of the stock traded hands, compared to its average volume of 27,452,044. The stock has a market capitalization of $13.05 billion, a PE ratio of 72.18, a PEG ratio of 3.91 and a beta of 2.14. Hims & Hers Health, Inc. has a twelve month low of $15.73 and a twelve month high of $72.98. The firm's 50-day moving average price is $50.71 and its two-hundred day moving average price is $45.77. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The firm had revenue of $544.83 million for the quarter, compared to analysts' expectations of $550.06 million. During the same quarter in the previous year, the company posted $0.06 earnings per share. The firm's quarterly revenue was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Truist Financial lowered their price target on Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating for the company in a report on Monday, August 18th. Citigroup reissued a "sell" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Canaccord Genuity Group reiterated a "buy" rating and set a $68.00 price target on shares of Hims & Hers Health in a research note on Friday, September 12th. Morgan Stanley restated an "equal weight" rating and set a $40.00 target price on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Finally, Zacks Research cut Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. Two analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat.com, Hims & Hers Health has an average rating of "Reduce" and an average price target of $38.92.

Institutional Investors Weigh In On Hims & Hers Health

Several institutional investors have recently made changes to their positions in HIMS. Smartleaf Asset Management LLC raised its holdings in Hims & Hers Health by 15.7% in the 1st quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company's stock valued at $49,000 after acquiring an additional 227 shares during the last quarter. Bessemer Group Inc. raised its position in shares of Hims & Hers Health by 105.8% in the second quarter. Bessemer Group Inc. now owns 607 shares of the company's stock valued at $30,000 after buying an additional 312 shares during the last quarter. True Vision MN LLC increased its position in shares of Hims & Hers Health by 3.6% in the second quarter. True Vision MN LLC now owns 9,376 shares of the company's stock worth $467,000 after acquiring an additional 328 shares in the last quarter. Allworth Financial LP grew its holdings in Hims & Hers Health by 20.0% during the 1st quarter. Allworth Financial LP now owns 2,006 shares of the company's stock valued at $56,000 after purchasing an additional 334 shares in the last quarter. Finally, Signaturefd LLC lifted its position in shares of Hims & Hers Health by 17.7% in the 1st quarter. Signaturefd LLC now owns 2,586 shares of the company's stock worth $76,000 after buying an additional 388 shares during the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.